Non-small-cell lung cancers: A heterogeneous set of diseases

Nature Reviews Cancer

Volumn 14, Issue 8, 2014, Pages 535-546

  Chen, Zhao ^a   Fillmore, Christine M ^b,c,d   Hammerman, Peter S ^a   Kim, Carla F ^b,c,d   Wong, Kwok Kin ^a,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PATIENT; GENETIC HETEROGENEITY; GENOME; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS;

EID: 84904860154     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3775     Document Type: Review

References (176)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013
3. Ettinger, D. S. et al. Non-Small Cell Lung Cancer, Version 2.2013. J. Natl Compr. Canc. Netw. 11, 645-653 (2013
4. Davidson, M. R., Gazdar, A. F. & Clarke, B. E. The pivotal role of pathology in the management of lung cancer. J. Thorac. Dis. 5, S463-S478 (2013
5. Langer, C. J., Besse, B., Gualberto, A., Brambilla, E. & Soria, J. C. The evolving role of histology in the management of advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 5311-5320 (2010
6. Rock, J. R., Randell, S. H. & Hogan, B. L. M. Airway basal stem cells: A perspective on their roles in epithelial homeostasis and remodeling. Dis. Model. Mech. 3, 545-556 (2010
7. Lu, Y. et al. Evidence that Sox2 overexpression is oncogenic in the lung. PLoS ONE 5, http://dx.doi. org/10.1371/journal.pone.0011022 (2010
8. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002 (Pubitemid 34716871)
9. Santos, E. et al. Malignant activation of a K ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223, 661-664 (1984 (Pubitemid 14186799)
10. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004 (Pubitemid 38637993)
11. Paez, J. G. et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004 (Pubitemid 38720929)
12. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004 (Pubitemid 39209661)
13. Shepherd, F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005 (Pubitemid 41058344)
14. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007 (Pubitemid 46799492)
15. Fernandez-Cuesta, L. et al. CD74 NRG1 fusions in lung adenocarcinoma. Cancer Discov. 4, 415-422 (2014
16. Kohno, T. et al. KIF5B RET fusions in lung adenocarcinoma. Nature Med. 18, 375-377 (2012
17. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007 (Pubitemid 350235027)
18. Soda, M. et al. Identification of the transforming EML4 ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007 (Pubitemid 47206930)
19. Stephens, P. et al. Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526 (2004
20. The Cancer Genome Atlas Research Network (TCGA). Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012
21. Vaishnavi, A. et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nature Med. 19, 1469-1472 (2013
22. Weiss, J. et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl. Med. 2, 62ra93 (2010
23. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008
24. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012
25. Heist, R. S. & Engelman, J. A. Snapshot: Non-small cell lung cancer. Cancer Cell 21, 448-448.e2 (2012
26. Guagnano, V. et al. FGFR genetic alterations predict for sensitivity to NVP BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2, 1118-1133 (2012
27. Hammerman, P. S. et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 1, 78-89 (2011
28. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013
29. The Cancer Genome Atlas Research Network (TCGA). Comprehensive molecular profiling of lung adenocarcinoma. Nature http://dx.doi.org/10.1038/ nature13385 (2014
30. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014
31. Govindan, R. et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121-1134 (2012
32. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009
33. Sun, N. et al. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer. Clin. Cancer Res. 19, 5136-5145 (2013
34. Tan, F. et al. Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. Mol. Cell Proteomics 11, M111.008821 (2012
35. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nature Med. 19, 1423-1437 (2013
36. DuPage, M. et al. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 19, 72-85 (2011
37. Murdoch, C., Muthana, M., Coffelt, S. B. & Lewis, C. E. The role of myeloid cells in the promotion of tumour angiogenesis. Nature Rev. Cancer 8, 618-631 (2008
38. Xiao, Z. et al. The pivotal role of IKKα in the development of spontaneous lung squamous cell carcinomas. Cancer Cell 23, 527-540 (2013
39. Vignaud, J. M. et al. The role of platelet-derived growth factor production by tumor-Associated macrophages in tumor stroma formation in lung cancer. Cancer Res. 54, 5455-5463 (1994
40. Zaynagetdinov, R. et al. A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J. Immunol. 187, 5703-5711 (2011
41. Bellocq, A. et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: Induction by tumor-derived interleukin 8 and relation to clinical outcome. Am. J. Pathol. 152, 83-92 (1998 (Pubitemid 28028049)
42. Houghton, A. M. et al. Neutrophil elastase-mediated degradation of IRS 1 accelerates lung tumor growth. Nature Med. 16, 219-223 (2010
43. Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Rev. Immunol. 11, 519-531 (2011
44. Brahmer, J. R. et al. Safety and activity of anti PD L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012
45. Topalian, S. L. et al. Safety, activity, and immune correlates of anti PD 1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
46. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD 1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008
47. Forde, P. M., Kelly, R. J. & Brahmer, J. R. New strategies in lung cancer: Translating immunotherapy into clinical practice. Clin. Cancer Res. 20, 1067-1073 (2014
48. Akbay, E. A. et al. Activation of the PD 1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3, 1355-1363 (2013
49. Xu, C. et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD L1 expression. Cancer Cell 25, 590-604 (2014
50. Ancrile, B., Lim, K. H. & Counter, C. M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 21, 1714-1719 (2007 (Pubitemid 47076470)
51. Gao, S. P. et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL 6 production in human lung adenocarcinomas. J. Clin. Invest. 117, 3846-3856 (2007 (Pubitemid 350224094)
52. Visvader, J. E. Cells of origin in cancer. Nature 469, 314-322 (2011
53. Tata, P. R. et al. Dedifferentiation of committed epithelial cells into stem cells in vivo. Nature 503, 218-223 (2013
54. Chaffer, C. L. et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. 108, 7950-7955 (2011
55. Kwon, M. & Berns, A. Mouse models for lung cancer. Mol. Oncol. 7, 165-177 (2013
56. Kim, C. et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823-835 (2005 (Pubitemid 40806415)
57. Tiozzo, C. et al. Deletion of Pten expands lung epithelial progenitor pools and confers resistance to airway injury. Am. J. Respir. Crit. Care Med. 180, 701-712 (2009
58. Ventura, J. J. et al. p38α MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nature Genet. 39, 750-758 (2007 (Pubitemid 46848588)
59. Xu, X. et al. Evidence for type II cells as cells of origin of K Ras-induced distal lung adenocarcinoma. Proc. Natl Acad. Sci. USA109, 4910-4915 (2012
60. Desai, T. J., Brownfield, D. G. & Krasnow, M. A. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 507, 190-194 (2014
61. Mainardi, S. et al. Identification of cancer initiating cells in K Ras driven lung adenocarcinoma. Proc. Natl Acad. Sci. USA 111, 255-260 (2014
62. Rowbotham, S. P. & Kim, C. F. Diverse cells at the origin of lung adenocarcinoma. Proc. Natl Acad. Sci. USA 111, 4745-4746 (2014
63. Sutherland, K. D. et al. Multiple cells of origin of mutant K Ras-induced mouse lung adenocarcinoma. Proc. Natl Acad. Sci. USA 111, 4952-4957 (2014
64. Giangreco, A. et al. β Catenin determines upper airway progenitor cell fate and preinvasive squamous lung cancer progression by modulating epithelial-mesenchymal transition. J. Pathol. 226, 575-587 (2012
65. Ji, H. et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807-810 (2007 (Pubitemid 47266337)
66. Malkoski, S. P. et al. Role of PTEN in basal cell derived lung carcinogenesis. Mol. Carcinog. http://dx.doi. org/10.1002/mc.22030 (2013
67. Beck, B. & Blanpain, C. Unravelling cancer stem cell potential. Nature Rev. Cancer 13, 727-738 (2013
68. Li, F., Tiede, B., Massague, J. & Kang, Y. Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res. 17, 3-14 (2007 (Pubitemid 46096419)
69. Jiang, F. et al. Aldehyde dehydrogenase 1 is a tumor stem cell-Associated marker in lung cancer. Mol. Cancer Res. 7, 330-338 (2009
70. Lau, A. N. et al. Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J. 33, 468-481 (2014
71. Liu, J. et al. Lung cancer tumorigenicity and drug resistance are maintained through ALDHhiCD44hi tumor initiating cells. Oncotarget 4, 1698-1711 (2013
72. Sullivan, J. P. et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on Notch signaling. Cancer Res. 70, 9937-9948 (2010
73. Zheng, Y. et al. A rare population of CD24+ITGB4+Notchhi cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell 24, 59-74 (2013
74. Curtis, S. J. et al. Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell 7, 127-133 (2010
75. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011
76. Song, H. et al. Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc. Natl Acad. Sci. USA 109, 17531-17536 (2012
77. Park, K. S. et al. Characterization of the cell of origin for small cell lung cancer. Cell Cycle 10, 2806-2815 (2011
78. Sutherland, K. D. et al. Cell of origin of small cell lung cancer: Inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 19, 754-764 (2011
79. Gazdar, A. F., Girard, L., Lockwood, W. W., Lam, W. L. & Minna, J. D. Lung cancer cell lines as tools for biomedical discovery and research. J. Natl Cancer Inst. 102, 1310-1321 (2010
80. Dow, L. E. & Lowe, S. W. Life in the fast lane: Mammalian disease models in the genomics era. Cell 148, 1099-1109 (2012
81. Levy, M. A., Lovly, C. M. & Pao, W. Translating genomic information into clinical medicine: Lung cancer as a paradigm. Genome Res. 22, 2101-2108 (2012
82. Shaw, A. T., Hsu, P. P., Awad, M. M. & Engelman, J. A. Tyrosine kinase gene rearrangements in epithelial malignancies. Nature Rev. Cancer 13, 772-787 (2013
83. Camidge, D. R. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol. 13, 1011-1019 (2012
84. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009
85. Shaw, A. T. et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 12, 1004-1012 (2011
86. Sequist, L. V. et al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. AACR Meet. [Abstr] CT326 (2014
87. Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120ra17 (2012
88. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005 (Pubitemid 40271173)
89. Shaw, A. T. et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189-1197 (2014
90. Walter, A. O. et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M mediated resistance in NSCLC. Cancer Discov. 3, 1404-1415 (2013
91. Cross, D. A. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. http://dx.doi. org/10.1158/2159-8290.CD-14-0337 (2014
92. Yonesaka, K. et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86 (2011
93. Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-Targeted therapy in lung cancer. Nature Genet. 44, 852-860 (2012
94. Ercan, D. et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2, 934-947 (2012
95. Lin, L. & Bivona, T. G. Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother. Res. Pract. 2012, 817297 (2012
96. Bivona, T. G. et al. FAS and NF κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471, 523-526 (2011
97. Xu, K. et al. EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent. Science 338, 1465-1469 (2012
98. Chen, Z. et al. A murine lung cancer co clinical trial identifies genetic modifiers of therapeutic response. Nature 483, 613-617 (2012
99. Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Med. 14, 1351-1356 (2008
100. Janne, P. A. et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 14, 38-47 (2013
101. Lim, S. M. et al. Therapeutic targeting of oncogenic K Ras by a covalent catalytic site inhibitor. Angew. Chem. Int. Ed Engl. 53, 199-204 (2014
102. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K RasG12C inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551 (2013
103. Bass, A. J. et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genet. 41, 1238-1242 (2009
104. Iwakawa, R. et al. MYC amplification as a prognostic marker of early-stage lung adenocarcinoma identified by whole genome copy number analysis. Clin. Cancer Res. 17, 1481-1489 (2011
105. Lin, C. Y. et al. Transcriptional amplification in tumor cells with elevated c Myc. Cell 151, 56-67 (2012
106. Engelman, J. A. & Janne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14, 2895-2899 (2008
107. Grosso, J. F. & Jure-Kunkel, M. N. CTLA 4 blockade in tumor models: An overview of preclinical and translational research. Cancer Immun. 13, 5 (2013
108. Lee, D. W., Barrett, D. M., Mackall, C., Orentas, R. & Grupp, S. A. The future is now: Chimeric antigen receptors as new targeted therapies for childhood cancer. Clin. Cancer Res. 18, 2780-2790 (2012
109. Tseng, D. et al. Anti CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T cell response. Proc. Natl Acad. Sci. USA 110, 11103-11108 (2013
110. Zhang, B. CD73: A novel target for cancer immunotherapy. Cancer Res. 70, 6407-6411 (2010
111. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006 (Pubitemid 44917502)
112. Schoenfeld, J. et al. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 70, 10150-10160 (2010
113. Yuan, J. et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol. Res. 2, 127-132 (2014
114. Lee, J. H. et al. Lung stem cell differentiation in mice directed by endothelial cells via a BMP4 NFATc1 thrombospondin 1 axis. Cell 156, 440-455 (2014
115. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012
116. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010
117. Shimamura, T. et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin. Cancer Res. 19, 6183-6192 (2013
118. Liu, Y. et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1 mutant lung cancer. Cancer Discov. 3, 870-879 (2013
119. Molina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S. & Downward, J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov. 3, 548-563 (2013
120. Orita, H. et al. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin. Cancer Res. 13, 7139-7145 (2007 (Pubitemid 350276900)
121. Shackelford, D. B. et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23, 143-158 (2013
122. Hughes, L. A. et al. The CpG island methylator phenotype: Whats in a name?. Cancer Res. 73, 5858-5868 (2013
123. Losman, J. A. & Kaelin, W. G. Jr. What a difference a hydroxyl makes: Mutant IDH, (R)-2 hydroxyglutarate, and cancer. Genes Dev. 27, 836-852 (2013
124. Shinjo, K. et al. Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis 33, 1277-1285 (2012
125. Chen, Z. et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4 ALK fusion oncogene. Cancer Res. 70, 9827-9836 (2010
126. Ji, H. et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-Targeted therapies. Cancer Cell 9, 485-495 (2006 (Pubitemid 43832191)
127. Chen, Z. et al. Co clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin. Cancer Res. 20, 1204-1211 (2014
128. Jackson, E. L. et al. The Differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280-10288 (2005 (Pubitemid 41743720)
129. Oliver, T. G. et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 24, 837-852 (2010
130. Blasco, R. B. et al. c Raf, but not B Raf, is essential for development of K Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 19, 652-663 (2011
131. Puyol, M. et al. A synthetic lethal interaction between K Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63-73 (2010
132. Savino, M. et al. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS ONE 6, e22284 (2011
133. Soucek, L. et al. Modelling Myc inhibition as a cancer therapy. Nature 455, 679-683 (2008
134. Soucek, L. et al. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 27, 504-513 (2013
135. Zhang, W. C. et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148, 259-272 (2012
136. Rock, J. R. et al. Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc. Natl Acad. Sci. USA 106, 12771-12775 (2009
137. Hegab, A. E. et al. Novel stem/progenitor cell population from murine tracheal submucosal gland ducts with multipotent regenerative potential. Stem Cells 29, 1283-1293 (2011
138. Rock, J. R. & Hogan, B. L. M. Epithelial progenitor cells in lung development, maintenance, repair, and disease. Annu. Rev. Cell Dev. Biol. 27, 493-512 (2011
139. Rawlins, E. L. et al. The role of Scgb1a1+ Clara cells in the long-Term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell 4, 525-534 (2009
140. Teixeira, V. H. et al. Stochastic homeostasis in human airway epithelium is achieved by neutral competition of basal cell progenitors. eLife 2, http://dx.doi.org/ 10.7554/eLife.00966#sthash.XxrCqaIk.dpuf (2013
141. Teisanu, R. M., Lagasse, E., Whitesides, J. F. & Stripp, B. R. Prospective Isolation of Bronchiolar Stem Cells Based Upon Immunophenotypic and Autofluorescence Characteristics. Stem Cells 27, 612-622 (2009
142. Barkauskas, C. E. et al. Type 2 alveolar cells are stem cells in adult lung. J. Clin. Invest. 123, 3025-3036 (2013
143. Chapman, H. A. et al. Integrin α6β4 identifies an adult distal lung epithelial population with regenerative potential in mice. J. Clin. Invest. 121, 2855-2862 (2011
144. Tropea, K. A. et al. Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am. J. Physiol. Lung Cell. Mol. Physiol. 302, L829-L837 (2012
145. Zacharek, S. J. et al. Lung stem cell self-renewal relies on BMI1 dependent control of expression at imprinted loci. Cell Stem Cell 9, 272-281 (2010
146. Rock, J. R. et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl Acad. Sci. USA 108, E1475-E1483 (2011
147. McQualter, J. L., Yuen, K., Williams, B. & Bertoncello, I. Evidence of an epithelial stem/ progenitor cell hierarchy in the adult mouse lung. Proc. Natl Acad. Sci. USA 107, 1414-1419 (2010
148. Hegab, A. E. et al. Isolation and in vitro characterization of basal and submucosal gland duct stem/progenitor cells from human proximal airways. Stem Cells Translat. Med. 1, 719-724 (2012
149. Kajstura, J. et al. Evidence for human lung stem cells. New Engl. J. Med. 364, 1795-1806 (2011
150. Marek, L. et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol. Pharmacol. 75, 196-207 (2009
151. Liao, R. G. et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 73, 5195-5205 (2013
152. Xu, L. et al. Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res. 72, 3302-3311 (2012
153. Davies, K. D. et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin. Cancer Res. 18, 4570-4579 (2012
154. Takeuchi, K. et al. RET, ROS1 and ALK fusions in lung cancer. Nature Med. 18, 378-381 (2012
155. Wang, S. E. et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10, 25-38 (2006
156. McDermott, U. et al. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-α activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 69, 3937-3946 (2009
157. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K ras. Genes Dev. 15, 3243-3248 (2001 (Pubitemid 34008190)
158. Mascaux, C. et al. The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-Analysis. Br. J. Cancer 92, 131-139 (2005 (Pubitemid 40188446)
159. De Raedt, T. et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 20, 400-413 (2011
160. Paik, P. K. et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J. Clin. Oncol. 29, 2046-2051 (2011
161. Kawano, O. et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 54, 209-215 (2006 (Pubitemid 44764916)
162. Marks, J. L. et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 68, 5524-5528 (2008
163. Licciulli, S. et al. Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53. Cancer Res. 73, 5974-5984 (2013
164. Westhoff, B. et al. Alterations of the Notch pathway in lung cancer. Proc. Natl Acad. Sci. USA 106, 22293-22298 (2009
165. Issaeva, I. et al. Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth. Mol. Cell. Biol. 27, 1889-1903 (2007
166. Takawa, M. et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 102, 1298-1305 (2011
167. Yang, H. et al. Tumor development is associated with decrease of TET gene expression and 5 methylcytosine hydroxylation. Oncogene 32, 663-669 (2013
168. Gao, Q. et al. Deletion of the De novo DNA methyltransferase Dnmt3a promotes lung tumor progression. Proc. Natl Acad. Sci. USA 108, 18061-18066 (2011
169. Ohta, T. et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 68, 1303-1309 (2008 (Pubitemid 351346836)
170. Singh, A. et al. Dysfunctional KEAP1 NRF2 interaction in non-small-cell lung cancer. PLoS Med. 3, e420 (2006
171. Wang, Y., Zhang, Z., Kastens, E., Lubet, R. A. & You, M. Mice with alterations in both p53 and Ink4a/ Arf display a striking increase in lung tumor multiplicity and progression: Differential chemopreventive effect of budesonide in wild-Type and mutant A/J mice. Cancer Res. 63, 4389-4395 (2003 (Pubitemid 36951008)
172. Lou-Qian, Z. et al. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: A systematic review and meta-Analysis. PLoS ONE 8, e54970 (2013
173. Mitsudomi, T., Hamajima, N., Ogawa, M. & Takahashi, T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-Analysis. Clin. Cancer Res. 6, 4055-4063 (2000
174. Sanchez-Cespedes, M. et al. Inactivation of LKB1/ STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62, 3659-3662 (2002 (Pubitemid 34728843)
175. Iwanaga, K. et al. Pten inactivation accelerates oncogenic K ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res. 68, 1119-1127 (2008 (Pubitemid 351272230)
176. Soria, J. C. et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res. 8, 1178-1184 (2002